Weiss Asset Management LP Buys Shares of 6,683 Edwards Lifesciences Co. (NYSE:EW)

Weiss Asset Management LP acquired a new stake in Edwards Lifesciences Co. (NYSE:EWFree Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 6,683 shares of the medical research company’s stock, valued at approximately $510,000.

A number of other institutional investors have also recently bought and sold shares of EW. Vanguard Group Inc. grew its stake in Edwards Lifesciences by 0.6% in the third quarter. Vanguard Group Inc. now owns 51,633,416 shares of the medical research company’s stock valued at $3,577,163,000 after purchasing an additional 325,808 shares in the last quarter. Brown Advisory Inc. increased its holdings in Edwards Lifesciences by 20.1% during the fourth quarter. Brown Advisory Inc. now owns 18,181,420 shares of the medical research company’s stock worth $1,386,333,000 after buying an additional 3,048,274 shares during the last quarter. Wellington Management Group LLP lifted its stake in Edwards Lifesciences by 9.2% in the third quarter. Wellington Management Group LLP now owns 16,434,401 shares of the medical research company’s stock valued at $1,138,575,000 after acquiring an additional 1,390,427 shares during the last quarter. Norges Bank bought a new position in shares of Edwards Lifesciences in the 4th quarter valued at about $648,540,000. Finally, Northern Trust Corp raised its holdings in shares of Edwards Lifesciences by 3.9% in the 3rd quarter. Northern Trust Corp now owns 6,357,473 shares of the medical research company’s stock valued at $440,446,000 after purchasing an additional 241,347 shares during the period. Institutional investors and hedge funds own 79.46% of the company’s stock.

Insider Buying and Selling

In related news, VP Daniel J. Lippis sold 1,715 shares of the company’s stock in a transaction on Thursday, March 7th. The shares were sold at an average price of $90.98, for a total value of $156,030.70. Following the completion of the transaction, the vice president now directly owns 17,213 shares in the company, valued at $1,566,038.74. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Edwards Lifesciences news, VP Daniel J. Lippis sold 1,715 shares of the stock in a transaction that occurred on Thursday, March 7th. The shares were sold at an average price of $90.98, for a total transaction of $156,030.70. Following the transaction, the vice president now directly owns 17,213 shares in the company, valued at $1,566,038.74. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Bernard J. Zovighian acquired 580 shares of the stock in a transaction dated Monday, May 6th. The stock was acquired at an average price of $85.74 per share, with a total value of $49,729.20. Following the completion of the acquisition, the chief executive officer now owns 3,268 shares in the company, valued at approximately $280,198.32. The disclosure for this purchase can be found here. Over the last three months, insiders have sold 180,707 shares of company stock worth $16,034,814. Insiders own 1.27% of the company’s stock.

Analyst Upgrades and Downgrades

EW has been the topic of a number of recent analyst reports. Barclays boosted their target price on Edwards Lifesciences from $100.00 to $101.00 and gave the stock an “overweight” rating in a report on Tuesday, May 7th. Royal Bank of Canada upped their target price on Edwards Lifesciences from $95.00 to $101.00 and gave the company an “outperform” rating in a research report on Monday, April 15th. Citigroup raised Edwards Lifesciences from a “neutral” rating to a “buy” rating and lifted their price target for the stock from $98.00 to $105.00 in a report on Wednesday, May 22nd. StockNews.com upgraded Edwards Lifesciences from a “hold” rating to a “buy” rating in a research note on Monday, April 29th. Finally, OTR Global upgraded shares of Edwards Lifesciences from a “mixed” rating to a “positive” rating in a research note on Tuesday, March 26th. One investment analyst has rated the stock with a sell rating, five have given a hold rating and fourteen have assigned a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $94.31.

Get Our Latest Stock Report on EW

Edwards Lifesciences Stock Performance

Shares of NYSE EW traded down $0.02 during trading on Wednesday, reaching $87.02. 978,414 shares of the stock traded hands, compared to its average volume of 3,516,428. Edwards Lifesciences Co. has a 52-week low of $60.57 and a 52-week high of $96.12. The company has a 50-day moving average of $89.44 and a 200-day moving average of $82.06. The stock has a market capitalization of $52.44 billion, a P/E ratio of 37.59, a price-to-earnings-growth ratio of 3.22 and a beta of 1.10. The company has a debt-to-equity ratio of 0.08, a current ratio of 3.75 and a quick ratio of 2.67.

Edwards Lifesciences (NYSE:EWGet Free Report) last issued its quarterly earnings data on Thursday, April 25th. The medical research company reported $0.66 EPS for the quarter, beating the consensus estimate of $0.64 by $0.02. Edwards Lifesciences had a net margin of 23.01% and a return on equity of 22.86%. The company had revenue of $1.60 billion during the quarter, compared to analysts’ expectations of $1.58 billion. Analysts forecast that Edwards Lifesciences Co. will post 2.77 EPS for the current fiscal year.

Edwards Lifesciences Profile

(Free Report)

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.

Read More

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Co. (NYSE:EWFree Report).

Institutional Ownership by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.